Clinical Trials

    Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

    Investigator: Chinemerem Abanonu

    Study Coordinator: Frances Saubon

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT05633602

    Phone: 713.624.0724

    Protocol Number: PRO00037682

    Description


    This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent).